Neurology: High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation (HCT) for Relapsing-Remitting Multiple sclerosis (MS) is organized by American Academy of Neurology (AAN) and will be held during Feb 28, 2017 - Feb 28, 2020.
The target audience for this medical event is physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine. This CME Conference has been approved for a maximum of 0.75 AMA PRA Category 1 Credits.
Conference Objectives are :
Upon completion of the article by Nash et al, the participant should be able to:
• State the incidence of adverse events observed during this study in patients treated with high-dose immunosuppressive therapy and hematopoietic cell transplantation.
• Estimate the proportion of patients experiencing event-free survival following treatment in this study.
• Discuss changes in neurologic disability (as measured by the Expanded Disability Status Scale) observed following treatment in this study.
Additional details will be posted as soon as they are available.
Hematology Blood and Marrow Transplant, Immunotherapies, Hematopathology